While most of the debate, quite correctly, centers on a binary event (FDA approval of its Galleri test) and then on whether medical insurers cover the test, there's another huge consideration: its pricing.
Grail Stock Has Skyrocketed 171% in 6 Months.
Prior to The Motley Fool, Lee was a Civil Engineer and Investment Manager.
It always makes sense to look at the downside risk as well as the upside potential in a stock, and that's particularly the case with a speculative growth stock like a multi-cancer early detection (MCED) test company, Grail (NASDAQ: GRAL) .